Trial Profile

ENSIGN: Phase II Window of Opportunity Trial of Stereotactic Body Radiation Therapy and In Situ Gene Therapy Followed by Nivolumab in Metastatic Squamous or Non-Squamous Non-Small Cell Lung Carcinoma and Metastatic Uveal Melanoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aglatimagene besadenovec (Primary) ; Nivolumab (Primary) ; Valaciclovir (Primary)
Indications Non-small cell lung cancer; Uveal melanoma
Focus Therapeutic Use
Acronyms ENSIGN

13 Jan 2025 According to a Candel Therapeutics media release, company looking to report updated overall survival data for CAN-2409 from phase 2a clinical trial in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025.
17 Nov 2020 Status changed from recruiting to discontinued.
08 Mar 2018 Planned number of patients changed from 29 to 25.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com